ARIAD to present clinical data on ponatinib for CML at ASH Annual Meeting

NewsGuard 100/100 Score
Nov 30 2010

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that updated clinical data from a fully enrolled Phase 1 trial of its investigational, pan-BCR-ABL inhibitor, ponatinib, will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) being held in Orlando, Florida, December 4-7, 2010.

These Phase 1 findings in patients with resistant and refractory chronic myeloid leukemia (CML) will be featured in an oral presentation and will also be highlighted in a webcast investor meeting being held at ASH.

The schedule and locations for the investor meeting and oral presentation session are listed below:

Source:

ARIAD Pharmaceuticals, Inc.

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , ,

Comments (0)

Suggested Reading

LabVantage celebrates customer success with record number of software deployments in FY 2024
New urine-based test improves identification of high-grade prostate cancer
Pembrolizumab enhances breast cancer treatment regardless of age or menopausal status
Lancet Commission predicts sharp increase in global prostate cancer cases
Innovative levodopa infusion pump trial shows promise for reducing Parkinson's symptoms
Georgetown study raises concerns over aspirin's role in breast cancer treatment
Lab to plant: Scaling up API processes with Dr. James Mencel's guidance
Natural obesity fighters: How coffee, tea, and cocoa combat weight gain

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
Extended CPAP treatment boosts lung development in premature infants